APYX

Rating neutralAI Memo

Apyx Medical

As of 2026-09-11/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-11 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Q2 growth and FY2026 outlook reset • 2026-08-06

Base target: $3 / p=50% prob

Biggest risk

APYX remains a small, low-coverage medtech issuer whose product momentum must translate into durable utilization, improving losses, and adequate liquidity. Commercial-launch execution or weaker handpiece pull-through could reverse recent growth quickly.

Invalidation

Break below $2 or thesis failure.

What would change my mind?

Revenue growth accelerated to 22%, Surgical Aesthetics grew 28%, and AYON adoption plus the PowerLipo capability could reinforce device placements and recurring handpiece demand. The deterministic prior remains positive, with a 12.73% expected 120-day return, although this is a model estimate rather than company guidance.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-09-11

Base target

p=50%

Bull target

p=30%

Bear target

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

AYON PowerLipo rollout
AYON-led recurring-use growth
Revenue growth accelerated to 22%, Surgical Aesthetics grew 28%, and AYON adoption plus the PowerLipo capability could reinforce device placements and recurring handpiece demand.

BearKey bullets

AYON and PowerLipo adoption evidence is still early; positive surgeon feedback does not establish broad placement, utilization, or recurring-revenue durability.
Apyx reported an adjusted EBITDA loss in Q2, so revenue growth must translate into better operating leverage and cash generation.
Low analyst coverage and unavailable target-revision data increase valuation uncertainty and the risk of sharp price reactions to incremental news.

WatchKey bullets

Q2 growth and FY2026 outlook reset

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $3 (p=50%)

Target spread vs base: +28% / -35%

Scenario probabilities

Bull Target: $4 (p=30%)Base Target: $3 (p=50%)Bear Target: $2 (p=20%)

Commentary

Primary operating evidence is constructive, but external coverage is sparse and no sufficient social-sentiment data were supplied. The $2.89 September 10 anchor remains below the $4.16 pre-Q2-release close cited in the prior baseline, suggesting the market has not fully endorsed the improved operating narrative. Post-print analyst revisions, options skew, and current short-interest evidence are unavailable, supporting cautious monitoring rather than a high-conviction bullish conclusion.

As of 2026-09-11 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

AYON PowerLipo rollout
AYON-led recurring-use growth

Scenarios

Bull Target (Scenario probability)

$4 / p=30% prob

Base Target (Scenario probability)

$3 / p=50% prob

Bear Target (Scenario probability)

$2 / p=20% prob

Analysis 2026-09-11 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.55

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-06
Q2 growth and FY2026 outlook reset
Apyx reported Q2 revenue of $13.9 million, up 22%, with Surgical Aesthetics revenue up 28%, and maintained FY2026 revenue guidance of $59-$60 million versus the earlier $57.5-$58.5 million baseline. The results were furnished through an SEC 8-K, while the stored call transcript supplies the operating detail. [#SEC-8K-2026-08-06] [#PR-EARNINGS-2026-08-14]
Prob 100.00% • Move 8.00% • Priced-in 85.00%

Short-term Catalysts

Next few weeks

AYON PowerLipo rollout
2026-09-30
Expanded FDA 510(k) clearance and the limited launch of AYON's reusable power-liposuction handpiece create a near-term adoption test. Management cited positive initial surgeon feedback, but evidence of broad placements and utilization remains limited. [#PR-EARNINGS-2026-08-14]
Prob 65% • Move 16% • Priced-in 60%

Long-term Catalysts

Months to a year

AYON-led recurring-use growth
2026-12-31
The longer-term thesis requires AYON placements to translate into sustained generator and single-use handpiece demand. Four consecutive quarters of AYON sales and increased domestic handpiece volume are constructive, but durability, margins, and cash-generation remain unproven. [#PR-EARNINGS-2026-08-14] [#10-K-2026-03-10]
Prob 55% • Move 25% • Priced-in 45%

Risks

AYON and PowerLipo adoption evidence is still early; positive surgeon feedback does not establish broad placement, utilization, or recurring-revenue durability.
Apyx reported an adjusted EBITDA loss in Q2, so revenue growth must translate into better operating leverage and cash generation.
Low analyst coverage and unavailable target-revision data increase valuation uncertainty and the risk of sharp price reactions to incremental news.
The filing packet references secured debt under the Perceptive credit agreement, but the supplied excerpt does not quantify current covenant or liquidity headroom. [#SEC-10Q-2026-08-06]
The supplied peer set contains no clearly direct, similarly sized aesthetic-device competitor, limiting relative-valuation confidence.

Peers

Symbol	Summary
BSX	A scaled surgical-device commercialization benchmark, but its size, diversification, profitability, and end markets make it a loose valuation comparison rather than a direct AYON peer.
ABT	Useful only as a broad medical-device quality and execution benchmark; Abbott's diversified portfolio and substantially larger scale limit direct read-through.
EW	A reference point for mature medtech margins and execution, but structural-heart exposure makes operating and valuation comparisons to aesthetic body contouring weak.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-11

Loading AI feed…

Symbol

Summary

BSX

A scaled surgical-device commercialization benchmark, but its size, diversification, profitability, and end markets make it a loose valuation comparison rather than a direct AYON peer.

ABT

Useful only as a broad medical-device quality and execution benchmark; Abbott's diversified portfolio and substantially larger scale limit direct read-through.

A reference point for mature medtech margins and execution, but structural-heart exposure makes operating and valuation comparisons to aesthetic body contouring weak.